Mutation analysis of the ferritin L-chain gene in age-related cataract by Assia, Nurit et al.
Mutation analysis of the ferritin L-chain gene in age-related
cataract
Nurit Assia,1 Nitza Goldenberg-Cohen,1,2,3 Gideon Rechavi,1,4 Ninette Amariglio,1,4 Yoram Cohen5
(The first two authors contributed equally to this study)
1Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; 2The Pediatric Eye Research Laboratory, Felsenstein Medical
Research Center, Tel Aviv University Petach Tikva, Israel; 3Ophthalmology Department, Pediatric Division, Schneider Children’s
Medical Center of Israel, Petach Tikva, Israel; 4Cancer Research Center, Sheba Medical Center, Tel-Hashomer, Sackler Faculty
of Medicine, Tel Aviv University, Tel Aviv, Israel; 5Department of Obstetric and Gynecology, Sheba Medical Center, Tel Hashomer,
Israel
Purpose: To investigate whether acquired somatic mutations in the iron response element of the ferritin L-chain gene
account for the age-related cataract.
Methods: The 15 most prevalent point mutations causing hereditary hyperferritinemia cataract syndrome (HHCS) were
screened in patients with age-related cataract using MALDI-TOF Mass Spectrometry. DNA samples were obtained from
the lens capsules of patients following cataract surgery, and subjected to PCR amplification. Products were analyzed by
a Sequenom® mass spectrometer, and classified as a mutation or wild type according to molecular weight. For a positive
control, L-ferritin G32T mutation detected by direct sequencing in 3 members of an Israeli family known to be affected
by HHCS was used.
Results: DNA samples were isolated from the lens capsules of 90 patients, mean age 73.86, and screened for L-ferritin
mutations. While the G32T mutation was detected in all 3 positive control cases, all other patients were negative for the
15 mutations.
Conclusions: Somatic mutations in the iron response elements (IRE) of the L-ferritin gene are infrequent in the age-related
cataract. The role of L-ferritin genetic variations in the pathogenesis of age-related cataract is yet to be explored.
Cataract, or opacity of the intraocular lens, is the most
common cause of curable blindness worldwide. It is treated
by surgical removal of the native lens, and its replacement by
an artificial one. Cataracts may be classified by etiology into
the age-related cataract, the congenital and juvenile cataract,
or  the  cataract  secondary  to  trauma,  intraocular  diseases,
systemic  diseases,  or  exposure  to  noxious  agents  such  as
radiation or certain drugs. The age-related cataract is by far
the most prevalent type of cataract, and is attributed to changes
in the lens structure and composition due to oxidative damage
which occurs with aging [1,2]. The congenital cataract is rare,
and  reflects  mainly  genetically-caused  developmental
alterations in the lens and surrounding ocular tissues [3]. The
discovery of a broad variety of genes important for eye and
lens development has progressed greatly in the recent years
[3]. Nevertheless, there still remains a long list of mutations
to be characterized, indicating a broad genetic heterogeneity
which clinicians simply refer to as a “cataract” [3].
Serum ferritin is normally a marker of iron overload.
Ferritin genes are sited at chromosomes 19 and 11. Regulation
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of ferritin synthesis involves the interaction between an iron
regulatory  protein  (IRP)  and  part  of  the  ferritin  mRNA
designated the iron regulatory elements (IREs). A disorder of
ferritin synthesis resulting in hyperferritinemia in the absence
of  iron  overload  has  been  described  [4].  Hereditary
hyperferritinemia cataract syndrome (HHCS), a syndrome of
early-onset  cataract  and  hyperferritinemia,  is  caused  by
germline mutations in the iron response element (IRE) of the
ferritin L-chain (L-ferritin) gene suggesting that the ferritin
metabolism plays a crucial role in the pathogenesis of cataract
[5-8]. HHCS is an autosomal dominant disease caused by
mutations in the IRE of the L-ferritin gene [9]. It is not unusual
to observe increased levels of ferritin in apparently healthy
patients [10]. HHCS is a genetic condition characterized by a
bilateral nuclear cataract of early onset. This overexpression
of the L-chain in the lens causes bilateral nuclear cataracts,
which are the specific sign of this syndrome [10]. Cataract
morphology in HHCS is highly distinctive. Ophthalmological
assessment  of  patients  with  hyperferritinemia,  even  when
asymptomatic,  may  lead  to  a  correct  diagnosis  of  HHCS
[11].
Ferritin is an iron storage protein which binds excess iron
in cells. It consists of 24 heavy (H-chain, 21 kDa) or light (L-
chain, 19 kDa) subunits, in ratios varying in the different
tissues  [12,13].  Ferritin  synthesis  is  tightly  regulated  by
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2487plasma iron levels [14]. This regulation is achieved by the
high-affinity interaction between non-coding mRNA stem-
loop  structures  known  as  IREs  and  cytoplasmic  mRNA-
binding proteins known as IRPs [14]. The binding of IRP to
IRE in the 5′ untranslated regions (UTR) of ferritin blocks
translation and thus inhibits ferritin synthesis [12]. It has been
demonstrated  that  single  or  double  point  mutations  or
deletions in the stem-loop structure of the IREs of the ferritin
L-subunit gene (chromosome 19q13.1) are responsible for the
upregulation of ferritin [10]. When intracellular iron levels are
high, a cluster of [4Fe-4S] binds to IRPs, preventing their
binding to the IRE. This enables the translation of ferritin
which acts to sequester and store free excess iron. In iron
repletion states there is little interference in IRP and IRE
interaction; ferritin translation is blocked and free iron levels
rise [9].
HHCS arises from various point mutations or deletions
within  the  IRE  of  the  L-ferritin  gene,  leading  to  the
overexpression of the L-chains in ferritin [9,13]. Ever since
families with HHCS were first described in 1995, almost 30
germline mutations in the L-ferritin gene have been reported
[15]. However, to this day, the mechanism by which ferritin
mutations lead to cataract remains unclear.
Gorlaska et al. [13] showed the accumulation of L-chain-
enriched  ferritin  associated  with  cytoplasmic  inclusion
bodies.  The  formation  of  inclusion  bodies  in  older  lens
epithelial  cells,  indicates  the  possible  involvement  of
cytoplasmic  L-chain-enriched  ferritin  aggregates  in  the
formation of age-related cataract [13]. Several studies indicate
that ferritin and more specifically ferritin H-chains, offers
protection  against  UV  radiation.  The  same  group  [16]
described the effects of UV radiation on canine lens epithelial
cells  following  transfection  with  an  expression  vector
containing the coding sequence of either L- or H-chain cDNA.
UV  radiation  reduced  the  cell  numbers  of  L-chain
transfectants  by  half  whereas  H-chain  transfectants  were
protected [16]. As UV radiation is a known risk factor for the
development  of  cataract,  overexpression  of  L-chains  as  a
result  of  mutations  may  be  responsible  for  the  increased
susceptibility for the formation of a cataract.
No relevant symptoms other than visual impairment were
found  to  be  associated  with  the  HHCS  syndrome  [9].  A
marked phenotypic variability was observed, and similarly,
serum  ferritin  levels  varied  substantially  within  subjects
sharing the same mutation [9]. Well defined lens opacities
were not detectable either at birth or at 1 year of HHCS
newborn [9]. In a previous study, the lens ferritin content was
analyzed in two subjects who underwent cataract surgery at
different  ages,  with  different  cataract  morphology;  values
were similar and about 1,500 fold higher than in controls [9].
These observations suggested that in HHCS the cataract is not
necessarily  congenital  and  that  in  addition  to  the  IRE
genotype,  other  genetic  or  environmental  factors  may
modulate  the  phenotype,  especially  the  severity  of  the
cataract.
Based on the hypothesis that the ferritin metabolism plays
a crucial role in the pathogenesis of cataract, we theorized that
acquired somatic mutation in the lens capsular DNA may
account  for  age-related  cataract.  Such  mutations  could
possibly follow exposure to mutagenic insults/oxidative stress
such as UV radiation. Our assumption was that alterations of
the L-ferritin gene in lens capsular cells may lead to local
changes  in  the  ferritin  metabolism,  which  could  cause
instability of lens structures and ultimately cataract.
In this study we investigate the prevalence of 15 point
mutations within the IRE of the L-ferritin gene previously
shown to cause HHCS, in DNA obtained from lens capsules
of senile cataract extracted in cataract surgery.
METHODS
Patients: Ninety surgically excised anterior lens capsules and
lens material were collected with informed consent during
routine  cataract  surgery  in  Rabin  Medical  Center  (Petach
Tikva, Israel) between 2006 and 2007 with Institutional and
National Genetic Review Board approval and were used for
analysis. Patients’ records were reviewed for age, sex and
cataract type.
TABLE 1. POINT MUTATION IN THE L-FERRITIN 5’UTR.
Mutation Described by
T22G Cazzola et al. [20]
G41C Cremonesi et al. [21]
C18T Cazzola et al. [20]
C10T Cremonesi et al. [15]
C14G Cremonesi et al. [21]
C16T Cremonesi et al. [15]
C90T Cremonesi et al. [15]
G51C Camaschella et al. [22]
G32T/C/A Martin et al. [23], Kato & Casella [24], Cazzola et al. [20], Cicilliano et al. [25]
C33T Balas et al. [26]
C36G Cremonesi et al. [15]
C36A Mumford et al. [27]
A37G Cremonesi et al. [15]
C39T Balas et al. [26]
A40G/C Beaumont et al. [5]
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epithelial cells were suspended in 5 ml conservation medium
(PBS) and kept in 4 °C until isolation of genomic DNA. DNA
was  extracted  using  standard  SDS/proteinase  K  digestion
followed  by  phenol-chloroform  extraction  and  ethanol
precipitation.  DNA  concentrations  were  estimated  by
spectrophotometric (OD) quantification and diluted to 2.5–25
ng/μl.
Mutation detection: Scanning of mutations in the L-ferritin 5′
UTR regulatory sequence was performed using the MALDI-
TOF Sequenom (Sequenom, San Diego, CA) platform. We
constructed and validated a molecular assay that detects the
15 most common point mutations that have been reported in
the literature (Table 1).
Assay  design:  Simplex  SNP  assays  were  designed  using
Sequenom‘s  MassARRAY  Assay  Design  V3.1  software
(Sequenom). The assay design and the list of amplification
and extension primers are provided in Table 2 and Table 3.
Assay outline: 384-well plates containing 2.5–25 ng of DNA
in each well were subjected to PCR amplification reactions
following the specifications of Sequenom (See below, PCR
conditions section). After PCR, shrimp alkaline phosphatase
(Sequenom) was added to the samples to dephosphorylate
excess  dNTPs  to  prevent  their  future  incorporation  and
interference  with  the  primer  extension  assay.  Allele
discrimination  reactions  were  conducted  by  adding  the
extension primer assay, DNA polymerase, and a mixture of
dNTPs and ddNTPS to each well. MassExtend clean resin
(Sequenom) was added to the mixtures to remove extraneous
salts that could interfere with MALDI-TOF analysis.
Genotyping was determined by spotting an aliquot of
each sample onto a 384 SpectroChip (Sequenom), which was
subsequently analyzed by the chip-based matrix-assisted laser
desorption time-of-flight (MALDI-TOF) mass spectrometer
(Sequenom).  With  this  technique,  each  spotted  sample  is
analyzed using laser-mediated desorption and ionization of
the  extended  oligonucleotide  product.  This  results  in  the
acceleration of the oligonucleotide toward a detector. The
velocity  of  the  sample  is  proportional  to  oligonucleotide
length. As a result, time from laser-mediated desorption and
TABLE 2. ASSAY DESIGN.
Mutation ID Amplicon
length
Ext. primer
direction
Ext.
primer
mass
First
allele
call
First
allele
mass
Second
allele call
Second
allele
mass
Third
allele
call
Third
allele
mass
Fourth
allele call
Fourth
allele mass
T22G 111 R 5596.7 G 5869.9 T 6183.1        
G41C 120 F 5111.3 C 5384.5 G 5728.7        
C18T 111 R 5206.4 T 5503.6 C 5808.8        
C10T 111 F 5138.3 C 5411.5 T 5755.7        
C14G 111 F 5178.4 C 5451.5 G 5780.8        
C16T 111 F 5178.4 C 5451.5 T 5795.8        
C90T 109 F 5052.3 C 5325.5 T 5933.9        
G51C 114 F 5489.6 C 5762.8 G 6445.2        
G32T/C 111 R 5507.6 G 5780.8 A 5795.8T5804.8 C 6134
C33T 111 R 5467.6 T 5764.8 C 6070        
C36G 113 F 5174.4 C 5447.5 G 5800.8        
C36A 113 F 5174.4 C 5447.5 A 6387.2        
A37G 114 F 5134.3 A 5431.5 G 5760.7        
C39T 120 R 5105.3 T 5402.5 C 5722.7        
A40G/C 120 F 5391.5 C 5664.7 A 5688.7 G 6338.1    
TABLE 3. PRIMER LIST.
Mutation ID 1st-PCR primer 2nd-PCR primer Extension primer
L-ferritin-T22G ACGTTGGATGGATCTGTTCCGTCCAAACAC ACGTTGGATGATAAAAGAAGCCGCCCTAGC TGTTGAAGCAAGAGACAG
L-ferritin-G41C ACGTTGGATGTAAAAGAAGCCGCCCTAGCC ACGTTGGATGAGAGTCCCCGGATCTGTTC TGTCTCTTGCTTCAACA
L-ferritin-C18T ACGTTGGATGGATCTGTTCCGTCCAAACAC ACGTTGGATGATAAAAGAAGCCGCCCTAGC AAGCAAGAGACAGACCC
L-ferritin-C10T ACGTTGGATGATAAAAGAAGCCGCCCTAGC ACGTTGGATGGATCTGTTCCGTCCAAACAC GTCCCCTCGCAGTTCGG
L-ferritin-C14G ACGTTGGATGATAAAAGAAGCCGCCCTAGC ACGTTGGATGGATCTGTTCCGTCCAAACAC CCTCGCAGTTCGGCGGT
L-ferritin-C16T ACGTTGGATGATAAAAGAAGCCGCCCTAGC ACGTTGGATGGATCTGTTCCGTCCAAACAC TCGCAGTTCGGCGGTCC
L-ferritin-C90T ACGTTGGATGACAGTGTTTGGACGGAACAG ACGTTGGATGATGGTCCCGGAGGTTGCAAG TCCAGCCTCCGACCGCC
L-ferritin-G51C ACGTTGGATGGGTCTGTCTCTTGCTTCAAC ACGTTGGATGTTGCAAGCGGAGAGGAAATC CTTCAACAGTGTTTGGAC
L-ferritin-G32T/
C
ACGTTGGATGGATCTGTTCCGTCCAAACAC ACGTTGGATGATAAAAGAAGCCGCCCTAGC GTCCAAACACTGTTGAAG
L-ferritin-C33T ACGTTGGATGGATCTGTTCCGTCCAAACAC ACGTTGGATGATAAAAGAAGCCGCCCTAGC CGTCCAAACACTGTTGAA
L-ferritin-C36G ACGTTGGATGATAAAAGAAGCCGCCCTAGC ACGTTGGATGCGGATCTGTTCCGTCCAAA GGGTCTGTCTCTTGCTT
L-ferritin-C36A ACGTTGGATGATAAAAGAAGCCGCCCTAGC ACGTTGGATGCGGATCTGTTCCGTCCAAA GGGTCTGTCTCTTGCTT
L-ferritin-A37G ACGTTGGATGATAAAAGAAGCCGCCCTAGC ACGTTGGATGCCGGATCTGTTCCGTCCAAA GGTCTGTCTCTTGCTTC
L-ferritin-C39T ACGTTGGATGAGAGTCCCCGGATCTGTTC ACGTTGGATGTAAAAGAAGCCGCCCTAGCC TGTTCCGTCCAAACACT
L-ferritin-A40G/C ACGTTGGATGTAAAAGAAGCCGCCCTAGCC ACGTTGGATGAGAGTCCCCGGATCTGTTC TCTGTCTCTTGCTTCAAC
Molecular Vision 2010; 16:2487-2493 <http://www.molvis.org/molvis/v16/a266> © 2010 Molecular Vision
2489ionization  to  detector  signaling  (time  of  flight  –  TOF)  is
directly correlated with oligonucleotide mass.
The  resulting  spectra  were  converted  to  meaningful
genotype  data  using  SpectroTYPER-RT  software
(Sequenom), which interprets the spectral output based on
information  for  expected  allele-specific  oligonucleotide
lengths generated during the assay design phase(see above).
Since the sensitivity of the system was previously determined
to be limited to detecting only mutations composing over 1%–
3%  of  the  analyzed  DNA  [17],  results  were  reviewed
thoroughly.
PCR  conditions:  PCR  amplifications  were  performed  in
standard 384-well plates, a 5 µl final volume containing 10 ng
of template DNA, 0.1 U of Taq polymerase (HotStarTaq,
Qiagen, Valencia, CA), 0.2 mM of each dNTP, 200 nmol of
the appropriate primer (Forward and Reverse), 1 mM MgCl2
and 1× HotStar buffer.
PCR thermal cycling was performed in an ABI-9700
instrument for 15 min at 95 °C, followed by 4 cycles of 20 s
at 95 °C, 30 s at 65 °C and 60 s at 72 °C, 4 cycles of 20 s at
95 °C, 30 s at 58 °C, and 60 s at 72 °C and 38 cycles of 20 s
at 95 °C, 30 s at 53 °C and 60 s at 72 °C. This was followed
by incubation with 0.3 U Shrimp alkaline phosphates in total
volume of 7 µl for 20 min at 37 °C and 5 min at 85 °C.
The MassEXTEND® (Sequenom) assay was conducted
in 9 µl final volume containing 1 µM extension primer, 0.2 µl
of termination mix (50 nM each of ddA, dG, ddT and ddC)
and 1.25 U ThermoSequenase (SequenomA) in 0.22× PCR
buffer. The cycling conditions were: incubation for 2 min at
94 °C followed by 99 cycles of 5 s at 94 °C, 5 s at 52 °C and
5  s  at  72  °C.  Following  this  step,  3  µg  MassEXTEND®
cleanup resin (Sequenom) and 16 µl DDW were added to
remove extraneous salts.
Samsung  nanodispenser  was  used  to  apply  15  nl  of
extension products from each well of the sample plate onto
the SpectroChip (Sequenom). Mass spectra were recorded on
a Bruker Biflex MALDI-TOF mass spectrometer operated in
the linear mode, and were analyzed by MassARRAY Typer
software (Sequenom).
Result validation (positive control): Results were validated by
performing MALDI-TOF genotyping of 3 family members
positive for the G32T mutation previously detected by direct
DNA sequencing.
RESULTS
Ninety patients (40 men and 50 women) participated in the
study. The patients had undergone cataract surgery in Rabin
Medical Center (Petah Tikva, Israel) between the years 2006
and 2007. Patients were 54–91 years old at the time of surgery
(mean age 73.86).
The DNA samples were screened for 15 point mutations
in the IRE of the L-ferritin gene. One assay (testing for the
G51C mutation) failed constantly and was excluded from the
Figure 1. Representative spectra of the
C18T assay. The arrowhead indicates
the unextended primer. The bold arrow
indicates the wild type allele (C18). The
thin  arrow  indicates  the  potential
location of the mutated allele (C18T).
Top  panel:  A  template-free  control
sample. Bottom panel: Wild type allele.
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assay.
DNA samples from 3 HHCS patients positive for the
G32T germline mutation, as determined by direct sequencing,
were used as positive controls for the G32T/C assay. These
samples were analyzed using the MALDI-TOF technique and
the G32T mutation was detected in all 3 cases (Figure 2). The
corresponding  chromatogram  from  one  of  the  patients  is
shown in Figure 3.
The 15 most common HHCS-related somatic mutations
were not detected in our study group.
DISCUSSION
Discovering  an  association  between  acquired  somatic
mutations and the development of age-related cataract may
have  meaningful  clinical  implications.  Studying  such
mutations  could  lead  to  a  better  understanding  of  the
underlying  mechanisms  of  cataract,  and  perhaps  aid  in
preventing  rather  then  treating  one  of  the  world’s  most
common disorders in adults.
Based on the hypothesis that a disturbance in normal
ferritin metabolism causes lens opacification in patients with
HHCS, we screened adult age-related cataract tissue for the
15 most prevalent HHCS point mutations described in the
literature.
In this study, no mutations were detected in any of the 15
sites screened. However, these mutations represent only one
genetic syndrome of the different congenital disorders which
present with bilateral cataract. Although this study has not
shown a connection between acquired mutations in the L-
ferritin gene and age related cataract, such connections may
still exist with other genes already known to be involved in
congenital cataract.
It has been suggested in many studies that both genetics
and environment play a role in the pathogenesis of cataract.
Hammond et al. [18] reported in 2001 the relative contribution
of genes, environment and age in the evolution of cataract in
a study of pairs of monozygotic and dizygotic twins. The main
contribution of the genetic factor was for cortical cataract.
Francis  et  al.  [19]  hypothesized  in  1999  that  age-related
Figure 2. Result validation. The G32T
mutation  was  detected  by  direct
sequencing  in  three  Israeli  family
members  with  HHCS.  DNA  samples
from all three were also analyzed using
the  MALDI-TOF  technique  and  were
used as positive controls for the G32T
mutation. The arrowhead indicates the
unextended  primer.  The  bold  arrow
indicates the wild type allele. The thin
arrow indicates the mutated allele. Top
panel: A spectrum from a template-free
sample  (negative  control).  Middle
panel:  A  spectrum  from  a  patient
negative for the mutation. Bottom panel:
A spectrum from a subject with HHCS
(positive control).
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2491cataract involves “mild” mutations in the same genes involved
in congenital cataract, except that in the congenital form the
same genes are more severely affected.
This study explores a different model to explain cataract
formation. As opposed to other studies which focused on the
late expression of congenital genetic factors, the hypothesis
of this study was that the genetic changes may have been
acquired over the years.
For  genetic  variation  screening  we  chose  to  use  the
Sequenom®  technology  which  allows  for  large-scale
screening  of  mutations.  Applying  MALDI-TOF  mass
spectrometry enabled a relatively simple genetic analysis of
capsular DNA. The analysis was performed by the system,
which interpreted the particles’ time of flight and determined
whether alleles are wild type or mutant according to data
previously generated in the Assay Design phase. System error
rates were minimal, and most were false positive rather than
preventing recognition of a true mutation.
In conclusion, no mutations were detected in the study in
the IRE region of the L-ferritin gene. However, this does not
exclude the possibility of mutations in other regions in the L-
ferritin  gene,  H-ferritin  gene  or  other  genes  that  may
contribute to cataract formation. If such mutations will be
discovered, it may be possible to offer patients intervention at
earlier stages of the disease, and offer treatment targeting the
affected genes, that may delay or prevent the need for surgery.
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